Диссертация (1174208), страница 45
Текст из файла (страница 45)
38–45.125. Щекина, М. И. Роль гепатопротекторов в терапии пациентов сметаболическим синдромом / М. И. Щекина, М. С. Панчук // Consiliummedicum. Гастроэнтерология. – 2013. – № 1. – С. 65–68.126. Яковенко, Э. П. Фиброз печени: механизмы развития и вопросытерапии / Э. П. Яковенко, А. Н. Иванов, А. С. Прянишникова, А. В.
Яковенко,Н. А. Агафонова // Фарматека. – 2011. – № 12. – С. 16–22.127. Abenavoli, L. Role Of Adipokines And Cytokines In Non-Alcoholic FattyLiver Disease / L. Abenavoli, V. Peta // Rev. Recent Clin. Trials. – 2014. – V.9(3)/ – P. 134–40.293128. Abenavoli, L. Metabolic aspects of adult patients with nonalcoholic fattyliver disease / L. Abenavoli, N. Milic, L. Di Renzo, T. Preveden, M. MedicStojanoska, A.
De Lorenzo // World J. Gastroenterol. – 2016. – V. 22. – P. 7006–7016.129. Ahmed, A. Nonalcoholic Fatty Liver Disease Review: Diagnosis, Treatment,and Outcomes / А. Ahmed, R. J. Wong, S. A. Harrison // Clin. Gastroenterol.Hepatol. – 2015. – V.13 (12). P. 2062–70.130. Ahmed, A. Hige prevalence of hepatic fibrosis in the setting of coexistingdiabetes and hepatic steatosis: A case for selective screening in the generalpopulation? / A. Ahmed, B.
Ryan, M. D. Perumpail, A. Stephen, S. A. Harrison //Hepatology. – 2016. – № 63 (1). – P. 20–22.131. Alexander, M. Real world data reveal a diagnostic gap in non-alcoholic fattyliver disease / M. Alexander, A. K. Loomis, J. Fairburb-Beech, J. Van der Lei,T. Duarte-Salles, D. Prieto-Alhambra, D. Ansell, A. Pasqua, F.
Lapi, P. Rijnbeek,M. Mosseveld, P. Egger, S. Kendrick, D. M. Waterworth, N. Sattar, W. Alazawi //BMC Med. – 2018. V.16. – P.130–137.132. Almeda-Valdes, P. Common features of the metabolic syndrome andnonalcoholic fatty liver disease / P. Almeda-Valdes, N. Aguilar-Olivos, M. Uribe,N. Méndez-Sánchez // Rev. Recent Clin. Trials. — 2014. – V. 9. – P. 148–158.133. Alswat, K. Nonalcoholic fatty liver disease burden - Saudi Arabia andUnited Arab Emirates / K. Alswat, A. A.
Aljumah, F. M. Sanai, F. Abaalkhail,M. Alghamdi, W. K. Al Hamoudi, A. Al Khathlan, H. Al Quraishi, A. Al Rifai,M. Al Zaabi // Saudi J. Gastroenterol. – 2018. – V. 24 (4). – P. 211–219.134. Angulo, P. Simple noninvasive systems predict long-term outcomes ofpatients with nonalcoholic fatty liver disease / Р. Angulо, E. Bugianesi,E. S. Bjornsson,P.
Charatcharoenwitthaya,P. R. Mills,F. Barrera,S. Haflidadottir, C.P. Day, J. George // Gastroenterology. – 2013. – V. 145 (4). –P. 782–9.135. Angulo, P. Liver fibrosis, but no other histologic features, is associated withlong-term outcomes of patients with nonalcoholic fatty liver disease. / P. Angulo,294D.E. Kleiner,S.Dam-Larsen,L. A. Adams,E.
S. Bjornsson,P. Charatcharoenwitthaya, P. R. Mills, J. C. Keach, H. D. Lafferty, A. Stahler //Gastroenterology. – 2015. – V. 149 (2). P. 389–97.136. Amato, М.С. Visceral adiposity index: a reliable indicator of visceral fatfunction associated with cardiometabolic risk / M. C. Amato, C. Giordano, M.Galia // Diabetes Care. – V. 33. № 4. – P. 920–922.137. Armstrong, M. J. Liraglutide safety and efficacy in patients with nonalcoholic steatohepatitis (LEAN): A multicentre, double-blind, randomised,placebo-controlled phase 2 study. / M.
J. Armstrong, P. Gaunt, G. P. Aithal,D. Barton,D.Hull,R. Parker,J. M. Hazlehurst,K. Guo,G.Abouda,M. A. Aldersley // Lancet. – 2016. – V. 387. – P. 679–690.138. Assy, N. Fatty infiltration of liver in hyperlipidemic patients. / N. Assy,K. Kaita, D. Mymin, C. Levy, B. Rosser, G. Minuk // Dig. Dis. Sci. – 2000.
– V.45. – P. 1929–1934.139. Augustin, S. Non-alcoholic fatty liver disease: A poorly known pandemic /S. Augustin, I. Graupera, J. Caballeria // Med. Clin. (Barc). – 2017. – V. 149 (12).– P. 542–548.140. Ballestri, S. Risk of cardiovascular, cardiac and arrhythmic complications inpatients with nonalcoholic fatty liver disease / S. Ballestri, A. Lonardo, S.Bonapace // World J.
Gastroenterol. – 2014. – V. 20. – P. 1724–45.141. Bedogni, G. The Fatty Liver Index: a simple and accurate predictor ofhepatic steatosis in the general population. / G. Bedogni, S. Bellentani, L. Miglioli// BMC Gastroenterol. – 2006. – V. 6. – P. 33–38.142. Blachier, M. The burden of liver disease in Europe: a review of availableepidemiological data / M. Blachier, H.
Leleu, M. PeckRadozavljevic, D. C. Valva,F. Roudot Thoraval / J. Hepatol. – 2013. – № 58. – P. 593–608.143. Blais, P. Nonalcoholic fatty liver disease is underrecognized in the primarycare setting. / P. Blais, N. Husain, J. R. Kramer, M. Kowalkowski, H. El-Serag,F. Kanwal // Am.
J. Gastroenterol. – 2015. – V.110 (1). – P. 10–14.295144. Benda, L. Über das histologische Bild der Leberdystrophie und seineBeeinflussung durch agonale und postmortale Vorgänge / L. Benda, E. Rissel,H. Thaler // Virchows Archiv für pathologische Anatomie und Physiologie und fürklinische Medizin. – 1957.
– V. 330 (6). – P. 594–607.145. Bhatia, L. Improvement in non-alcoholic fatty liver disease severity isassociated with a reduction in carotid intima-media thickness progression /L. Bhatia, E. Scorletti, N. Curzen, G. F. Clough, P. C. Calder, C. D. Byrne //Atherosclerosis. – 2016. – V. 246. – P. 13–20.146. Bonapace, S. Nonalcoholic fatty liver disease is associated with leftventricular diastolic dysfunction in patients with type 2 diabetes / S.
Bonapace //Diabetes Care. – 2012. – № 35 (2). – P. 389–95.147. Browning, J. D. Prevalence of hepatic steatosis in an urban population in theUnited States: impact of ethnicity / J. D. Browning, L. S. Szczepaniak, R. Dobbins,P. Nuremberg // Hepatology. – 2004. – V. 40. – P. 1387–95.148. Buzzetti, E. Noninvasive Assessment of Fibrosis in Patients withNonalcoholic Fatty Liver Disease / E. Buzzetti, R. Lombardi, L. De Luca,E.
A. Tsochatzis // Int. J. Endocrinol. – 2015. – V. 19. – P. 123–134.149. Buzzetti, E. The multiple-hit pathogenesis of nonalcoholic fatty liver disease(NAFLD) / E. Buzzetti, M. Pinzani, E. A. Tsochatzis // Metabolism. – 2016. – V.65 (8). – P. 1038–48.150. Carey, E. Noninvasive tests for liver disease, fibrosis, and cirrhosis: Is liverbiopsy obsolete? / E.
Carey, W. D. Carey // Cleve. Clin. J. Med. – 2010. – V. 77(8). – P. 519–27.151. Castera, L. Prospective comparison of transient elastography, Fibrotest,APRI and liver biopsy for the assessment of fibrosis in chronic hepatitis C /L. Castera, J. Vergniol, J. Foucher / Gastroenterology. – 2005. – №128. – Р. 343–350.152. Chalasani, N. Who should be screened for NASH? / N. Chalasani // Ann. N.Y. Acad. Sci.
– 2013. – Vol. 1281. – P.106–22.296153. Chalasani, N. The diagnosis and management of nonalcoholic fatty liverdisease: practice guidance from the American Association for the Study of LiverDiseases / N. Chalasani, H. L. Bonkovsky, R. Fontana, W. Lee, A. Stolz,J. Talwalkar // Hepatology. – 2018. – V. 67 (1). – P.
328–57.154. Cobbina, E. Non-alcoholic fatty liver disease (NAFLD) – pathogenesis,classification, and effect on drug metabolizing enzymes and transporters /Е. Cobbina, F. Akhlaghi // Drug Metab. Rev. – 2017. – V. 49. – № 2. – P. 197–211.155. Cuthbertson, D. J. External validation of the fatty liver index and lipidaccumulation product indices, using 1H-magnetic resonance spectroscopy, toidentify hepatic steatosis in healthy controls and obese, insulin-resistant individuals/ D.
J. Cuthbertson, M. O. Weickert, D. Lythgoe, V. S. Sprung, R. Dobson,F. Shoajee-Moradie,M. Umpleby,A. F. Pfeiffer,E. L. Thomas,J. D. Bell,H. Jones, G. J. Kemp // Eur. J. Endocrinol. – 2014. – V. 171 (5). – P. 561–9.156. Day, C. P. Progression of NAFLD to diabetes mellitus, cardiovasculardisease or cirrhosis / C. P. Day, Q. M.
Anstee, G. Targher // Nat. Rev.Gastroenterol. Hepatol. – 2013. – Vol. 10. – P. 330–44.157. Del Chierico, F. Gut microbiota profiling of pediatric nonalcoholic fattyliver disease and obese patients unveiled by an integrated meta-omics-basedapproach / F. Del Chierico, V. Nobili, P. Vernocchi, A. Russo, C. Stefanis,D. Gnani, C. Furlanello, A. Zandonà, P. Paci, G.
Capuani // Hepatology. – 2017. –V. 65. – P. 451–464.158. Devereux, R. B. Echocardiographic determination of left ventricular mass inman / R. B. Devereux, N. Reicheck // Circulation. – 1977. – № 55. – Р. 613–618.159. Drapkina, O.M. Prevalence of nonalcoholic fatty liver disease in the RussionFederation: the open, multicenter, prospective study, DIREG I / О. М. Drapkina,Y. Evsyutina, V. Ivashkin // Am. J.
Clin. Med. Res. – 2015. – №3(2). – P. 31–36.160. European Association for the Study of the Liver (EASL). EuropeanAssociation for the Study of Diabetes (EASD). European Association for the Studyof Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the297management of non-alcoholic fatty liver disease // J. Hepatol.
– 2016. – V. 64 (6).– P. 1388–1402.161. Ekstedt, M. Fibrosis Stage is the strongest predictor for disease-specificmortality in NAFLD After Up to 33 Years of Follow-Up / M. Ekstedt, H.Hagstrom, P. Nasr, M. Fredrikson, S. Kechagias, R. Hultcrantz // Hepatology. –2015. – №61 (5). – P. 1547–1554.162. Ekstedt, M. Long-term follow-up of patients with NAFLD and elevated liverenzymes / M. Ekstedt, L. E.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
